Clinical trial
CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for…
NCT00211939 · Nabi Biopharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00211939 |
|---|---|
| Title | CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients |
| Official title | CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2) |
| Lead sponsor | Nabi Biopharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Calcinosis, Arteriosclerosis, Hyperparathyroidism, Secondary |
| Intervention type | Drug |
| Interventions | calcium acetate, sevelamer, atorvastatin |
| Enrollment | 203 |
| Start date | Jan 1, 2005 |
| Primary completion | Dec 1, 2006 |
| Completion | Mar 1, 2007 |
| First posted | Sep 21, 2005 |
| Last update posted | Jan 8, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: